DARE Stock Overview
Daré Bioscience, Inc., a biopharmaceutical company, identifies, develops, and markets products for women’s health in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Daré Bioscience, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.30 |
| 52 Week High | US$1.10 |
| 52 Week Low | US$0.27 |
| Beta | 1.21 |
| 1 Month Change | -38.27% |
| 3 Month Change | -6.58% |
| 1 Year Change | -70.17% |
| 3 Year Change | -80.82% |
| 5 Year Change | -71.61% |
| Change since IPO | -95.08% |
Recent News & Updates
Recent updates
We're A Little Worried About Daré Bioscience's (NASDAQ:DARE) Cash Burn Rate
Nov 07
We Think Daré Bioscience (NASDAQ:DARE) Needs To Drive Business Growth Carefully
Jul 21Is Daré Bioscience (NASDAQ:DARE) In A Good Position To Invest In Growth?
Mar 12Daré rises on positive data from early-to-mid-stage trial of intravaginal ring to treat menopause symptoms
Oct 17Daré Bioscience rises as company submits application to begin trial of non-hormonal contraceptive
Oct 10Dare Bioscience reports positive progress for cream for female sexual arousal disorder
Aug 29Daré Bioscience signs agreement with Organon for bacterial vaginosis therapy
Jun 30Will Daré Bioscience (NASDAQ:DARE) Spend Its Cash Wisely?
Apr 02Diving Back Into Daré Bioscience Again
Jan 07We Think Daré Bioscience (NASDAQ:DARE) Needs To Drive Business Growth Carefully
Nov 26Daré Bioscience's DARE-BV1 shows positive action in late-stage bacterial vaginosis study
Apr 26Diving Into Daré Bioscience
Jan 31Why Daré Bioscience, Inc. (NASDAQ:DARE) Could Be Worth Watching
Dec 22
Dare Bioscience EPS misses by $0.06
Nov 12Shareholder Returns
| DARE | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -39.1% | -1.5% | -3.2% |
| 1Y | -70.2% | 9.7% | 19.3% |
Return vs Industry: DARE underperformed the US Pharmaceuticals industry which returned 9.7% over the past year.
Return vs Market: DARE underperformed the US Market which returned 19.3% over the past year.
Price Volatility
| DARE volatility | |
|---|---|
| DARE Average Weekly Movement | 19.5% |
| Pharmaceuticals Industry Average Movement | 9.8% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: DARE's share price has been volatile over the past 3 months.
Volatility Over Time: DARE's weekly volatility has increased from 12% to 20% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 25 | Sabrina Johnson | darebioscience.com |
Daré Bioscience, Inc., a biopharmaceutical company, identifies, develops, and markets products for women’s health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older.
Daré Bioscience, Inc. Fundamentals Summary
| DARE fundamental statistics | |
|---|---|
| Market cap | US$29.70m |
| Earnings (TTM) | -US$30.16m |
| Revenue (TTM) | US$2.81m |
10.6x
P/S Ratio-1.0x
P/E RatioIs DARE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DARE income statement (TTM) | |
|---|---|
| Revenue | US$2.81m |
| Cost of Revenue | US$21.64m |
| Gross Profit | -US$18.83m |
| Other Expenses | US$11.33m |
| Earnings | -US$30.16m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.30 |
| Gross Margin | -670.62% |
| Net Profit Margin | -1,074.17% |
| Debt/Equity Ratio | 0% |
How did DARE perform over the long term?
See historical performance and comparison